Gilead Sciences (GILD) : Paloma Partners Management Co scooped up 137,554 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 184,831 shares of Gilead Sciences which is valued at $14,723,637.Gilead Sciences makes up approximately 0.57% of Paloma Partners Management Co’s portfolio.
Other Hedge Funds, Including , Venbio Select Advisor added GILD to its portfolio by purchasing 175,400 company shares during the most recent quarter which is valued at $13,972,364. Gilead Sciences makes up approx 4.96% of Venbio Select Advisor’s portfolio.Shamrock Asset Management boosted its stake in GILD in the latest quarter, The investment management firm added 50 additional shares and now holds a total of 226 shares of Gilead Sciences which is valued at $18,003. Gilead Sciences makes up approx 0.01% of Shamrock Asset Management’s portfolio. Marvin Palmer Associates Inc sold out all of its stake in GILD during the most recent quarter. The investment firm sold 14,075 shares of GILD which is valued $1,121,215.Bourgeon Capital Management boosted its stake in GILD in the latest quarter, The investment management firm added 4,400 additional shares and now holds a total of 6,900 shares of Gilead Sciences which is valued at $552,621. Gilead Sciences makes up approx 0.34% of Bourgeon Capital Management’s portfolio.Ftb Advisors reduced its stake in GILD by selling 4,764 shares or 7.67% in the most recent quarter. The Hedge Fund company now holds 57,381 shares of GILD which is valued at $4,560,068. Gilead Sciences makes up approx 0.60% of Ftb Advisors’s portfolio.
Gilead Sciences opened for trading at $78.38 and hit $78.805 on the upside on Wednesday, eventually ending the session at $78.22, with a gain of 0.44% or 0.34 points. The heightened volatility saw the trading volume jump to 8,232,697 shares. Company has a market cap of $103,224 M.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Upgraded by Jefferies to ” Buy” on Sep 6, 2016. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.